March 9 (Reuters) – Life sciences firm Agilent Technologies said on Monday that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million. Agilent said it will acquire California-headquartered Biocare Medical from Excellere Partners and GHO Capital Partners, and it expects the deal to close by the fourth […]
Health
Agilent to acquire Biocare Medical in $950 million all-cash deal
Audio By Carbonatix
March 9 (Reuters) – Life sciences firm Agilent Technologies said on Monday that it will acquire privately held clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million.
Agilent said it will acquire California-headquartered Biocare Medical from Excellere Partners and GHO Capital Partners, and it expects the deal to close by the fourth fiscal quarter of 2026.
Biocare is set to become part of Agilent’s Life Sciences and Diagnostics Markets unit.
Biocare Medical’s portfolio includes integrated tissue diagnostic products for cancer and infectious disease, and its website lists government and military laboratories among its customers.
Agilent, which has a market capitalization of $33.38 billion according to LSEG data, had reported first-quarter results in February that were largely in line with estimates, signaling stable demand for its medical tools and other equipment.
(Reporting by Gursimran Kaur in Bengaluru; Editing by Sherry Jacob-Phillips and Rashmi Aich)